TGFβtrap x TIGIT

Compass’ TGFβ x TIGIT bispecific is a novel therapy designed to neutralize TGFβ, a highly immunosuppressive cytokine that is overproduced by many tumors, while simultaneously blocking the immune inhibitory receptor TIGIT (T cell immunoreceptor with Ig and ITIM domains) commonly expressed on exhausted T and NK cells. Unlike other TIGIT blockers currently in development, Compass’ TIGIT blocker is a non-depleting, pure antagonistic antibody.